Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study

Guan, Xiaoni; Xu, Jing; Xiu, Meihong; Li, Xirong; Liu, Haixia; Wu, Fengchun

doi:10.1111/cns.13895

Cited by 5 publications

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 621 Previous report has shown that after 4 weeks of olanzapine monotherapy in schizophrenic patients, methyl n-methylaminobenzoate as response biomarkers in the kynurenine pathway is associated with treatment outcomes. 622 Metabolic profile alteration to molecular phenotype of psoriasis vulgaris patients showed that SM (d16:1/16:1) and Cer (d18:1/18:0) correlated with the biochemical indicators and could contribute to precision treatment. 623 Another study used metabolomic profiling and small metabolites (N-methylisoleucine, nornicotine, 2,3-dihydroxybutanoic acid) were able to discriminate rheumatoid arthritis patients with early response to methotrexate therapy.…”

Section: Enabling Precision Treatmentmentioning

confidence: 97%

Small molecule metabolites: discovery of biomarkers and therapeutic targets

Qiu

Cai

et al. 2023

Sig Transduct Target Ther

240

View full text Add to dashboard Cite

Metabolic abnormalities lead to the dysfunction of metabolic pathways and metabolite accumulation or deficiency which is well-recognized hallmarks of diseases. Metabolite signatures that have close proximity to subject’s phenotypic informative dimension, are useful for predicting diagnosis and prognosis of diseases as well as monitoring treatments. The lack of early biomarkers could lead to poor diagnosis and serious outcomes. Therefore, noninvasive diagnosis and monitoring methods with high specificity and selectivity are desperately needed. Small molecule metabolites-based metabolomics has become a specialized tool for metabolic biomarker and pathway analysis, for revealing possible mechanisms of human various diseases and deciphering therapeutic potentials. It could help identify functional biomarkers related to phenotypic variation and delineate biochemical pathways changes as early indicators of pathological dysfunction and damage prior to disease development. Recently, scientists have established a large number of metabolic profiles to reveal the underlying mechanisms and metabolic networks for therapeutic target exploration in biomedicine. This review summarized the metabolic analysis on the potential value of small-molecule candidate metabolites as biomarkers with clinical events, which may lead to better diagnosis, prognosis, drug screening and treatment. We also discuss challenges that need to be addressed to fuel the next wave of breakthroughs.

show abstract

Section: Enabling Precision Treatmentmentioning

confidence: 97%